Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting
The wide use of ruxolitinib, approved for treating primary and secondary myelofibrosis (MF), has revolutionized the landscape of these diseases. This molecule can reduce spleen volume and constitutional symptoms, guaranteeing patients a better quality of life and survival or even a valid bridge to b...
Main Authors: | Andrea Duminuco, Antonella Nardo, Bruno Garibaldi, Calogero Vetro, Anna Longo, Cesarina Giallongo, Francesco Di Raimondo, Giuseppe A. Palumbo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-12-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/11/24/7418 |
Similar Items
-
AIPSS‐MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib
by: Andrea Duminuco, et al.
Published: (2023-10-01) -
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis
by: Francesca Palandri, et al.
Published: (2023-10-01) -
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real‐life setting: An Italian MYNERVA Project
by: Giacomo Coltro, et al.
Published: (2023-04-01) -
Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future
by: Andrea Duminuco, et al.
Published: (2023-03-01) -
Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report
by: Meltem Aylı, et al.
Published: (2015-05-01)